tbuckley/cabot-search huggingface dataset:
FRI0137 Association between Number and Type of Different ACPA Fine Specificities and Parenchymal Lung Changes in High Resolution Computed Tomography in Patients with Early Rheumatoid Arthritis: Table 1.
Authors: V. Joshua, K. Chatzidionysiou, G. Reynisdottir, A.H. Hensvold, M. Hansson, L. Nogueira, A. Eklund, G. Serre, J. Grunewald, A.I. Catrina
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anti-CCP2 antibodies are associated with parenchymal lung changes in early RA. <h3>Objectives</h3> To examine the association between ACPA fine specificities and parenchymal lung changes in early RA. <h3>Methods</h3> Patients with newly diagnosed RA, glucocorticoids and DMARDs-naive, were included. High-resolution computed tomography (HRCT) was performed to assess parenchymal lung changes (ground glass changes, nodules, infiltrates or fibrosis). ImmunoCAP was used to detect RF IgA, RF IgM, anti-CCP2 IgA, anti-CCP2 IgG and ISAC microarray system was used to detect antibodies against 10 citrullinated (Cit) peptidic antigens: CCP-1 (Filaggrin), CEP-1 (α-enolase), Vim 2–17, Vim 60–75 (Vimentin), Fib β 36–52, Fib α 573, Fib α 591, Fib α 36–50, Fib β 60–74, Fib α 621–635 (Fibrinogen). Logistic regression was performed to examine associations between lung changes and autoantibodies, adjusted for age and sex. Due to risk for effect modification of smoking and co-linearity between smoking and Cit peptides, we stratified the cohort according to ever vs. never smokers. <h3>Results</h3> A total of 106 patients were included. The mean (SD) age was 57 (14) years. 69% were females; 73% were ever smokers; 70% were RF positive and 69% were positive for anti-CCP2. Parenchymal lung changes were found in 58 patients (54.7%). Higher age [≥65 vs &lt;65, OR (95% CI) =2.5 (1.1–5.9)], pos RF IgA [OR (95% CI) =2.7 (1.2–5.9)], pos CCP2 IgG [OR (95% CI) =2.3 (1.0–5.4)], ever smoking [OR (95% CI) =2.6 (1.1–6.2)] and pack-years above 24 [OR (95% CI) =6.9 (2.0–23.5)], were significant predictors of parenchymal lung changes. Some ACPA fine specificities were associated to parenchymal lung changes in ever smokers (table 1). Having five or more ACPA specificities at the time of diagnosis increased the risk of having lung changes in ever smokers by 6.6 times (table 1). <h3>Conclusions</h3> RF IgA, anti-CCP2 IgG, antibodies to Cit Fib and Cit Vim peptides were strongly associated to parenchymal lung changes in ever smokers with early RA. The more ACPA fine specificities, the higher the risk of parenchymal lung changes. <h3>Disclosure of Interest</h3> None declared
PWE-098 Missed Colorectal Cancer Following Colonoscopy, CT Colonography or Barium Enema: Abstract PWE-098 Table 1
Authors: D King, H Livett, S Prabhakaran, I Ahmad
Journal: Gut (2016)

<h3>Introduction</h3> Colonoscopy, CT colonography (CTC) and barium enema have been used to detect Colorectal Cancer (CRC). A diagnosis of CRC following a false-negative investigation represents a missed opportunity and may lead to adverse clinical outcomes. The literature describes various rates for missed CRC with some authors suggesting patients be consented for between 2–6%.<sup>1</sup> We present audit data from our NHS Trust looking at the miss rate of CRC following these investigations in both symptomatic and screened patients. <h3>Methods</h3> We retrospectively audited the computerised (EZNotes) case notes and investigations of patients with a diagnosis of CRC between January-December 2013. Patients were sourced from the Somerset cancer registry and National Bowel Cancer Audit (NBOCA). We recorded whether patients had been investigated with colonoscopy, CTC or barium enema in the preceding 6 to 36 month period, obtaining a rate for false-negative investigations i.e a missed diagnosis of CRC. <h3>Results</h3> 385 patients had a diagnosis of CRC made within the period. Of 291 colonoscopies performed, 17 missed a diagnosis made in the preceding 6–36 month period equating to a 6% miss rate. The mean time delay between date of colonoscopy in PCCRCs and date of diagnosis was 613 days (range 201–1075). 38% of these missed cancers were in the right colon and 39% were found in the rectum and sigmoid. 62% of patients had concomitant diverticular disease. Of 32 CTCs undertaken 3 missed a CRC and of 11 barium enemas performed 5 CRCs were missed. 11% of patients presented as emergencies, 14% via bowel cancer screening and the remaining 75% presented with symptoms, from surveillance or with a significant family history. <h3>Conclusion</h3> Colonoscopy is the best test for detecting CRC but missed cancers still occur. The missed CRC rate found in this audit was comparable to published series. Several factors seem to be associated with false negative investigations; right sided cancers are often cited as more susceptible to misses due to anatomy and technical difficulties. We found that rectal cancers were missed in comparable numbers to right sided cancers, and suggest that particular care is taken when diverticular disease is present. Extra time should be taken in the caecum and hepatic flexure as “review areas” where misses are more likely to occur. Ongoing audit as well as improved endoscopy training and technology will ensure that rates of missed CRC are reduced. <h3>Reference</h3> 1 Bressler B, <i>et al</i>. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. <i>Gastroenterology</i>. 2007 Jan;<b>132</b>(1):96–102. <h3>Disclosure of Interest</h3> None Declared
Akt Signalling Inhibition Promotes The Ex Vivo generation Of Minor Histocompatibility Antigen-Specific CD8+ Memory Stem T Cells
Authors: Anniek B. van der Waart, Noortje van der Weem, Luca Gattinoni, Nicolaas PM Schaap, Robbert van der Voort, Willemijn Hobo, Harry Dolstra
Journal: Blood (2013)
ω-3 Polyunsaturated Fatty Acids to Prevent Psychosis
Authors: John M. Kane, Christoph U. Correll
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
AB0888 Childhood Arthritis as The First Manifestation of Inflammatory Bowel Disease
Authors: V. Bittermann, E. Quesada-Masachs, A. Remesal, S. Murias, C. Modesto
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Joint involvement is the most common extraintestinal manifestation in children with inflammatory bowel disease and it may appear years before its diagnosis. <h3>Objectives</h3> To describe the characteristics of arthritis associated with inflammatory bowel disease (IBD) in children. <h3>Methods</h3> A retrospective, cross sectional, descriptive study was performed including patients of two Pediatric Rheumatology Units from tertiary hospitals with arthritis as the first manifestation of an inflammatory bowel disease. <h3>Results</h3> Data for all JIA patients controlled in 2 tertiary centers were analyzed. 14 patients met the inclusion criteria (10 females/4 males). Median age of onset of joint manifestation was 7 years (3–14.3 years). Median age of onset of gastrointestinal symptoms was 17.1 years (8.8–29.8 years). Musculoskeletal manifestations preceded the intestinal manifestations about 12 years (0.3–21.8 years). Most frequent JIA subtype was extended/persistent oligoarticular form (36% of all cases). Polyarticular type of JIA was present in 3 patient, enthesitis related arthritis in 2 patients and undifferentiated JIA in 2 patients. One patient had reactive arthritis. The most common type of IBD was Crohn9s disease (60%). The most frequently affected joint was the knee (57%). In 2 patients the initial affected joint was the hip. ANA were positive in 6 children (40%) and 3 had HLA B27 positive (20%). Fecal calprotectin was normal in 10 patients studied. All patients have received systemic corticosteroids and 70% needed articular infiltration. 85% of patients required biological treatment to control the articular symptoms and/or gastrointestinal (mostly adalimumab) associated with DMARDs in a high percentage. <h3>Conclusions</h3> It isn9t common that the joint involvement precede the digestive symptoms in IBD. In our series the most frequent category was the oligoarticular form with negative ANA and this presented later than usual. They present an evolution with difficult control of the flares. A large number of patients needed biological treatment to control the articular manifestations. These results support the need for new biomarkers that could detect subclinical intestinal disease in children. <h3>Disclosure of Interest</h3> None declared
A Novel Hemoglobin Binding Peptide Increases Intracellular Heme and Potentiates Hemoglobin-Induced HO-1 Levels in Endothelial Cells
Authors: Madelyn S. Hanson, Timothy C. Flewelen, Hao Xu, Kirkwood A Pritchard, Nancy J Wandersee, Neil Hogg, Cheryl A. Hillery
Journal: Blood (2011)
The β-HPV Subtypes—Cornerstone of the Next-Generation Vaccine
Authors: Jad Chahoud, Alyssa G. Rieber, Stephen K. Tyring
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
PTU-043 Prospective Study of the Diagnostic Yield from Histological Versus Cytological Preparation of Specimens Acquired Using Standard EUS FNA Needles
Authors: V Mahesh, A Banerjee, C Walsh, K Davies, S Shaktawat
Journal: Gut (2016)

<h3>Introduction</h3> Improvements in the EUS FNA needle design and optimisation of tissue acquisition techniques have resulted in better diagnostic yield (DY). Recently there has been considerable interest in histological processing of tissue acquired using newer ‘core’ FNA needles, which are often more expensive than standard needles. We hereby provide preliminary data on DY of tissue acquired using standard FNA needles. <h3>Aim</h3> To compare the diagnostic yield of histological versus cytological preparation of tissue acquired using standard EUS FNA needle and to compare overall diagnostic yield. <h3>Methods</h3> Prospective non-blinded randomised study . All patients undergoing EUS guided FNA from November 2015 to February 2016, for solid lesions were included. FNA was performed using Cook Echotip Ultra<sup>TM</sup> or Boston Scientific Expect<sup>TM</sup> 19, 22 or 25 G needles based on stock availability and location of the lesion, Olympus EU-ME2<sup>TM</sup> processor and linear echoendoscopes was used. All patients had 4 passes done with the same needle, specimens from each pass were randomly collected in BD Cytorich<sup>TM</sup> or Formalin. Each preservative had 2 passes of material. EUS FNA was performed by one endosonographer and two trainees employing standard FNA technique and suction, pathology reported by 5 different cytopathologists. All cytology specimens were processed by the biomedical scientists for cell block ± smear preperation. Cellularity of the sample were simply graded as adequate or inadequate. Histology processing was performed as standard. <h3>Results</h3> In total 21 patients had EUS FNA performed, mean age 65.5±12.1 years, 14 M:7 F. Final diagnoses include 5 pancreatic malignancies, 5 GIST/NET, 2 malignant nodes, 1 lymphoma, 6 benign, 2 non-diagnostic. 19 G needle was used in 15 patients, 22 G in 4 patients and 25 G in 2 patients. Diagnosis was made in 15/21 (71.4%) from cytology specimens and 19/21 (90.4%) from combined cytology and histologically processed specimens. An incremental diagnostic gain in 4/21 specimens, i.e. 19% by processing samples as histology in addition to standard cytology. No statistical significance was seen on univariate or multivariate logistic regression analysis for tumour size (≥2 cm), route of FNA or size of needle. Limitations of the study include small sample size, no blinding being used for randomisation of the FNA specimen. <h3>Conclusion</h3> Our ‘proof of concept’ study with preliminary results show that adequate samples can be obtained for histological processing even with standard FNA needles and incremental gain in DY by additionally processing specimens as histology. Data from our randomised blinded trial would shed further light into this important area. <h3>Disclosure of Interest</h3> None Declared
Ruxolitinib, a Janus Kinase (JAK)-1 and -2 Inhibitor Modulates Microrna (miR) Levels in Patients with Myelofibrosis (MF): miR Levels Might Predict MF Treatment Outcome
Authors: Taghi Manshouri, Zeev Estrov, Liza Knez, Ying Zhang, Ross L Levine, Hagop M. Kantarjian, Srdan Verstovsek
Journal: Blood (2011)
Heme Concentration As a Biomarker of Sickle Cell Disease Severity: Its Role in Steady-State and in Crisis Patients
Authors: Magda Oliveira Seixas Carvalho, Larissa Carneiro Rocha, João Henrique Oliveira Reis, Théo de Araújo Santos, Valma Maria Lopes do Nascimento, Mauricio Batista Carvalho, Nívea Farias Luz, Valeria de Matos Borges, Marilda Souza Goncalves
Journal: Blood (2015)
FRI0062 Obesity Is Associated with Worse Clinical Outcomes Yet Limited Radiographic Progression in Early Rheumatoid Arthritis: Table 1.
Authors: A. Levitsky, S. Saevarsdottir, K. Brismar, K. Hambardzumyan, C. Lourdudoss, R.F. van Vollenhoven
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In RA, being overweight or obese has previously been shown to be associated with worse clinical outcomes (1, 2), yet also less radiographic damage (2, 3). <h3>Objectives</h3> To confirm if body mass index (BMI) is associated with worse clinical disease activity or inversely associated with radiographic outcomes in early RA. <h3>Methods</h3> BMI, categorized as normal (&lt;25, n=141), overweight (25–29.9, n=74), and obese (≥30, n=43), was available in 258 patients who were enrolled in the Swedish pharmacotherapy (SWEFOT) trial. After initial methotrexate for 3 months, non-responders were randomized to triple therapy or anti-TNF therapy, while responders continued on methotrexate. Disease activity (DAS28), functional impairment (HAQ), VAS-pain, and radiographic damage (Sharp van der Heijde score, SHS) were evaluated regularly. Here, results are shown at 24 months of follow-up. <h3>Results</h3> Treatment allocation and baseline outcome measures did not differ across the BMI categories. In a dose-response manner, higher BMI at baseline was associated with worse clinical outcomes over 24 months (DAS28, HAQ, and VAS-pain) (Table). Patients with normal (58%) or overweight (50%) BMI had a proportionally greater chance of attaining 24-month clinical remission (DAS28&lt;2.6) than obese patients (23.1%) (OR 3.2 [95% CI 1.6–6.3], p&lt;0.001; OR 2.2 [95% CI 1.2–4.1], p=0.007, respectively). Among absolute radiographic scores, no significant differences were observed, yet radiographic progression (ΔSHS≥1, baseline-24 months) was halted more frequently (56.3%) among obese patients than normal/overweight patients combined (37.6%) (OR 1.9 [95% CI 1.0–3.6], p=0.049) (obese vs. normal (40%), OR 1.7 [95% CI 0.9–3.1], p=0.101; obese vs. overweight (32.7%), OR 1.8 [95% CI 1.1–3.2], p=0.032). <h3>Conclusions</h3> Obesity at diagnosis was found to be a strong predictor of worse long-term clinical outcomes in early RA – including disease activity, functional impairment, and pain; thus confirming previous findings. Nonetheless – as has also been previously shown – obesity was associated with a better chance of halting radiographic progression. <h3>References</h3> Sandberg ME, et al. Ann Rheum Dis. 2014 Nov;73(11):2029–33; Vidal C, et al. J Rheumatol. 2015 Dec;42(12):2261–9; Baker JF, et al. Ann Rheum Dis. 2014 Nov;73(11):1923–8 <h3>Disclosure of Interest</h3> A. Levitsky: None declared, S. Saevarsdottir: None declared, K. Brismar: None declared, K. Hambardzumyan: None declared, C. Lourdudoss: None declared, R. van Vollenhoven Grant/research support from: AbbVie, BMS, GSK, Pfizer, Roche, and UCB, Consultant for: AbbVie, Biotest, BMS, Crescendo, GSK, Janssen, Lilly, Merck, Pfizer, Roche, UCB, and Vertex
Haploidentical Hematopoietic Stem Cell Transplantation In Hematologic Malignancies with G-CSF Mobilized Bone Marrow Plus Peripheral Blood Stem Cells Grafts without T Cell Depletion: a Single Center Report of 29 Cases
Authors: Hengxiang Wang, Hongmin Yan, Zhidong Wang, Mei Xue, Ling Zhu, Jing Liu, Li Ding
Journal: Blood (2010)
Impaired Maturation and Survival of T Lymphocytes, B Lymphocytes, and NK Cells in Mice Lacking Gimap5/Ian5.
Authors: Ryan D. Schulteis, Xuezhi Dai, Haiyan Chu, Brandon Edwards, Dipica Haribhai, Calvin B. Williams, Subramanium Malarkannan, Hessner J. Martin, Kwitek E. Anne, Åke Lernmark, Jack Gorski, Demin Wang, Hartmut Weiler
Journal: Blood (2006)
Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.
Authors: Kazuhito Yamamoto, Kensei Tobinai, Atae Utsunomiya, Kunihiro Tsukasaki, Naokuni Uike, Kimiharu Uozumi, Masao Tomonaga, Koji Matsushima, Kenya Shitara, Shiro Akinaga, Ryuzo Ueda
Journal: Blood (2008)
IL-15 Plays a Critical Role in CD8+ T-Cell Recovery after Allogeneic Transplantation.
Authors: Frances T. Hakim, Kenton Allen, Jesse M. Carson, Michael Boyiadzis, Sarfraz A. Memon, Robert Dean, Jeanne Odom, Alan Wayne, Daniel Fowler, Michael R. Bishop, Ronald E. Gress
Journal: Blood (2005)
S32 Epidemiology of chronic obstructive pulmonary disease (COPD) in the uk: findings from the british lung foundation’s ‘respiratory health of the nation’ project
Authors: N Snell, D Strachan, R Hubbard, J Gibson, K Gruffydd-Jones, I Jarrold
Journal: Thorax (2016)

<h3>Background</h3> We performed an analysis of UK respiratory disease epidemiology covering 2004–2012. Findings pertaining to COPD are presented here. <h3>Methods</h3> Prevalence and incidence rates were estimated from The Health Intelligence Network database representing ∼5 per cent of the population. Mortality figures came from official government statistics. WHO data were used for international mortality comparisons and numbers of hospital admissions/inpatient bed-days. <h3>Results</h3> An estimated 1.2 million people (2% of the population) have diagnosed COPD – considerably more than the 835,000 estimated by the Department of Health in 2011 – making COPD the second most common lung disease in the UK, after asthma. Prevalence has increased by 27% in the last decade. Incidence fell 2004–2008 but has been stable since with just under 115,000 new diagnoses in 2012. Men are more likely to be diagnosed with COPD and to die from it than women. COPD is rare under 40 and becomes commoner with age, affecting 9% of those aged &gt;70. COPD prevalence, incidence and mortality rates are highest in Scotland and the north of England. Prevalence and incidence are over twice as great in the most deprived population quintile than in the least. Nearly 30,000 people die from COPD each year, making it the second greatest cause of death from lung disease and the UK's fifth biggest killer. Mortality increased from 2004–2012. The UK COPD mortality rate ranks third in Europe. COPD accounts for over 140,000 hospital admissions and over a million bed days each year across the UK (1.7% of all hospital admissions and bed days). 97% of these admissions are for emergency care. London has notably more hospital admissions for COPD than other regions with similar prevalence. <h3>Conclusions</h3> Gender, location, and deprivation differences in COPD epidemiology probably largely reflect differences in smoking behaviour. COPD continues to represent an enormous burden on UK health services.